Extended Data Fig. 4: TLC-6665 reduces hepatic target gene expression in vivo. | Nature Medicine

Extended Data Fig. 4: TLC-6665 reduces hepatic target gene expression in vivo.

From: An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial

Extended Data Fig. 4: TLC-6665 reduces hepatic target gene expression in vivo.The alternative text for this image may have been generated using AI.

(a-b) Schematics illustrating evaluation of TLC-6665 in DIO mice (a) and HFD-fed Zucker diabetic fatty (ZDF) rats (b). (c-d) Liver target engagement assessed by expression of LXR target genes in DIO mice (c, n = 10/group) and ZDF rats (d, n = 6/group) after treatment with TLC-6665. Significance were calculated by two-tailed Mann-Whitney U test and adjusted by BH adjustment.

Source data

Back to article page